More positive news about another new blood cancer therapy:

Bethesda-based Micromet Inc. announced Monday that it would begin late-stage European trials for its lead drug candidate, blinatumomab, in adults with a certain type of leukemia.

Micromet said it expects the pivotal trial to test the “efficacy, safety and tolerability” of the drug in as many as 130 patients with minimal residual disease positive B-precursor acute lymphoblastic leukemia, following chemotherapy treatment. The company hopes the drug will slash relapse rates for the cancer.

Acute lymphoblastic leukemia, or ALL, is a cancer affecting the white blood cells and is the most common form of leukemia found in children, according to the National Cancer Institute, though this Micromet treatment is focusing only on adults. Minimal residual disease describes the remaining cancer cells in the body after treatment.

Micromet projects enrollment in the pivotal trial will take two years to complete and span 70 cancer centers in the U.S. and Europe.

In the second phase of studies for this drug, Micromet (NASDAQ: MITI) showed that its treatment had a high rate of response in patients, news that caused its stock to soar and allowed the company to initiate several rounds of stock sales to help pay for this new clinical trial.

Good luck to all!
Feel good and keep smiling! Pat & Pattie

Leave a Reply